Related Experiment Videos
Meningococcal vaccines
N E Rosenstein1, M Fischer, J W Tappero
1Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. nar5@cdc.gov
Insights
Developing new meningococcal vaccines is crucial for global disease control. Current vaccines have limitations, necessitating innovative approaches for broader, long-lasting protection against meningococcal disease.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Current polysaccharide vaccines for meningococcal disease have limitations in efficacy, particularly in young children.
- Protein-polysaccharide conjugate vaccines offer potential but face cost and accessibility challenges.
- Outer membrane protein (OMP) vaccines show promise for serogroup B but are limited by antigenic variability.
Purpose of the Study:
- To review the limitations of existing meningococcal vaccines.
- To explore alternative vaccine development strategies.
- To highlight the challenges in creating a universal meningococcal vaccine.
Main Methods:
- Review of existing literature on meningococcal vaccines.
- Analysis of the immunological responses to different vaccine types.
- Discussion of the antigenic properties of Neisseria meningitidis.
Main Results:
- Polysaccharide vaccines induce suboptimal immunity.
- Conjugate vaccines are expensive and may not reach underserved populations.
- OMP vaccines provide strain-specific protection due to antigen variability.
Conclusions:
- Novel vaccine approaches are needed to overcome current limitations.
- A universal vaccine targeting common antigens across all serogroups is ideal.
- Neisseria meningitidis's immune evasion mechanisms present a significant challenge for future vaccine development.
Abstract:
Global control and prevention of meningococcal disease depends on the further development of vaccines that overcome the limitations of the current polysaccharide vaccines. Protein-polysaccharide conjugate vaccines likely will address the marginal protective antibody responses and short duration of immunity in young children derived from the A, C, Y, and W-135 capsular polysaccharides, but they will be expensive to produce and purchase, and may not offer a practical solution to the countries with greatest need. In addition, OMP vaccines have been tested extensively in humans and hold some promise in the development of a serogroup B vaccine, but are limited by the antigenic variability of these subcapsular antigens and the resulting strain-specific protection. Elimination of meningococcal disease likely will require a novel approach to vaccine development, ideally incorporating a safe and effective antigen or antigens common to all meningoccocal serogroups. As a solely human pathogen, however, N. meningitidis has developed many tools with which to evade the human immune system, and likely will pose a formidable challenge for years to come.